On 17 January 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Bosulif 100 mg and 500 mg film-coated tablets intended for the treatment of chronic myelogenous leukaemia (CML). Bosulif was designated as an orphan medicinal product on 4 August 2010.
See Home page for link to ema website and further details.
NICE STA on bosutinib has now passed the draft scope stage and CMLSg will represent patients at the committee meeting in June this year. We also need a patient representative currently treated with bosutinib to present their story to the committee.
Please contact me if you or someone you know is willing to act as a 'patient expert'.
Thanks
Sandy